<DOC>
	<DOCNO>NCT01781052</DOCNO>
	<brief_summary>This prospective , non-interventional , multi-center study document observational data subject routine treatment Pulmonary Arterial Hypertension , functional class III inhale Iloprost administer I-Neb AAD ( Adaptive Aerosol Delivery ) device . The observation period subject cover one year treatment period inhale Ventavis . For subject , investigator delegate collect data define case report form initial visit , routine follow-up visit 6 month final visit 12 month .</brief_summary>
	<brief_title>Observational Description Compliance Daily Ventavis Use Via Insight Program Class III Pulmonary Arterial Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Male female subject age â‰¥18 year Newly Treated Ventavis treat Ventavis le 6 month , I Neb AAD device application , describe SmPC ( Summary Product Characteristics ) , complement Insight With Pulmonary Arterial Hypertension , Group I Dana point Pulmonary Hypertension Classification . WHO ( World Health Organization ) /NYHA ( New York Heart Association ) Functional class III Able willing give write informed consent participation study Key contra indication : Hypersensitivity active substance excipients . Conditions effect Ventavis platelet might increase risk haemorrhage ( e.g . active peptic ulcer , trauma , intracranial haemorrhage ) . Severe coronary heart disease unstable angina ; Myocardial infarction within last six month ; Decompensated cardiac failure close medical supervision ; Severe arrhythmias ; Cerebrovascular event ( e.g . transient ischaemic attack , stroke ) within last 3 month . Pulmonary hypertension due venous occlusive disease . Congenital acquire valvular defect clinically relevant myocardial function disorder related pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Iloprost Compliance</keyword>
</DOC>